186mg Capsules for Cresemba contain 186mg of Isavuconazonium sulfate = 100mg Isavuconazonium
In Europe and Canada, the 100mg capsule is equivalent to the 186mg capsule in the United States - both contain the same amount of active ingredient and are made in the same factories.
Cresemba in Europe is manufactured at the following 2 factories: Almac Pharma Services (Ireland) Limited Finnabair Industrial Estate Dundalk Co. Louth A91 P9KD Ireland Almac Pharma Services Limited Seagoe Industrial Estate Craigavon, Co. Armagh BT63 5UA United Kingdom (Northern Ireland)
Information about Cresemba (Isavuconazonium)
Cresemba, with the generic name isavuconazonium, is an antifungal medication used to treat certain serious fungal infections. It is a prodrug that is converted into its active form, isavuconazole, in the body. Isavuconazole belongs to the class of triazole antifungals, which work by inhibiting the synthesis of ergosterol, a key component of fungal cell membranes.
Product Highlights
Cresemba is an advanced antifungal medication used to treat serious fungal infections, including invasive aspergillosis and mucormycosis.
Its broad-spectrum efficacy and minimal effect on the QT interval make it a valuable choice for patients needing effective fungal infection treatment.
Key Ingredient
Isavuconazonium
Key Benefits
Effective against a range of fungal pathogens, including Aspergillus and Mucorales species.
Available in both oral and intravenous formulations, allowing flexibility depending on patient needs and conditions.
Generally well-tolerated with a manageable side effect profile compared to some other antifungal agents.
Direction of Use
Take Cresemba capsules with or without food. The typical dosage for adults is 372 mg (two 186 mg capsules) taken orally once daily.
Administered as an intravenous infusion, typically 200 mg every 8 hours for the first 48 hours, followed by 200 mg once daily.
Dosage Regimen for CRESEMBA
Loading Dose
Maintenance Dose1
CRESEMBA for Injection
372 mg2 of isavuconazonium sulfate per vial
1 reconstituted vial (372 mg2 ) intravenously every 8 hours for 6 doses (48 hours)
1 reconstituted vial (372 mg2 ) intravenously once daily
CRESEMBA Capsules
186 mg3 of isavuconazonium sulfate per capsule
2 capsules (372 mg2 ) orally every 8 hours for 6 doses (48 hours)
2 capsules (372 mg2 ) orally once daily
Safety Concerns
Use with caution in patients with liver disease; liver function tests should be monitored.
Isavuconazole can interact with other medications, especially those affecting the CYP3A4 enzyme. Caution is advised when used with drugs that are strong inhibitors or inducers of CYP3A4.
Unlike some other triazoles, isavuconazole has minimal effect on the QT interval, reducing the risk of significant QT prolongation.
Avoid Cresemba (Isavuconazonium) If
Avoid use in patients with a known hypersensitivity to isavuconazonium, isavuconazole, or any component of the formulation.
Use is not recommended in patients with severe hepatic impairment unless the benefits outweigh the risks.
Avoid co-administration with strong inducers or inhibitors of CYP3A4, unless carefully monitored or alternative therapies are considered.
